Literature DB >> 33877715

Liver transplantation for congenital hepatic fibrosis.

W Kelly Wu1, Ioannis A Ziogas1, Manhal Izzy2, Anita K Pai3, Einar T Hafberg3, Lea K Matsuoka1, Sophoclis P Alexopoulos1.   

Abstract

Congenital hepatic fibrosis (CHF) is a hereditary fibrocystic disease that can progress to portal hypertension and recurrent cholangitis requiring liver transplantation (LT). It can be associated with renal pathology and need for kidney transplantation (KT). We describe the clinical characteristics and outcomes of patients undergoing liver transplantation alone (LTA) and simultaneous liver-kidney transplantation (SLKT) for CHF using the Unites States Scientific Registry of Transplant Recipients. 197 patients who received LT for CHF between 2002 and 2018 were identified - 87 (44.2%) received SLKT, 110 (55.8%) received LTA. The 1-, 3-, and 5-year patient survival were 99.0%, 96.2%, and 94.6%. The 1-, 3-, and 5-year liver graft survival were 94.9%, 91.1%, and 89.6%. No significant differences in patient or liver graft survival were observed between the SLKT and LTA groups, or between pediatric and adult recipients. 53.3% of patients with CHF necessitating LT also have significant renal disease requiring KT. Kidney graft survival for isolated KT prior to LT were poorer compared to KT performed simultaneously or after LT. Both LTA and SLKT for CHF are associated with excellent long-term outcomes in pediatric and adult patients. This article is protected by copyright. All rights reserved.

Entities:  

Keywords:  Scientific Registry of Transplant Recipients; ciliopathy; hepatorenal fibrocystic disease; polycystic kidney disease; simultaneous liver kidney transplantation

Year:  2021        PMID: 33877715     DOI: 10.1111/tri.13884

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  1 in total

Review 1.  Placental Immune Tolerance and Organ Transplantation: Underlying Interconnections and Clinical Implications.

Authors:  Jin-Yu Sun; Rui Wu; Jiang Xu; Hui-Ying Xue; Xiao-Jie Lu; Jiansong Ji
Journal:  Front Immunol       Date:  2021-08-03       Impact factor: 7.561

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.